BioCentury | Feb 13, 2021
Finance

Qiming readies to kick off Chinese New Year with a first for Hong Kong exchange

...said Qiming typically invests 60-70% of its RMB funds...
...which manages nine U.S. dollar and six RMB funds...
BioCentury | Jan 27, 2021
Deals

Jan. 26 Quick Takes: Sanofi to manufacture more than 100M doses of Comirnaty; plus Qiming, Nirogy, Takeda-Evozyne and Vir

Under a new deal with Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), Sanofi (Euronext:SAN; NASDAQ:SNY) will produce more than 100 million doses of COVID-19 vaccine Cormirnaty in Europe in 2021. Sanofi spokesperson Nicolas Kressmann said...
BioCentury | Dec 9, 2020
Emerging Company Profile

How D3 Bio is building its biomarker-driven pipeline

George Chen’s D3 Bio is prioritizing  its internal pipeline so it can be choosy about in-licensed assets. The Shanghai company unveiled a $200 million series A round on Nov. 17 that was backed...
BioCentury | May 28, 2019
Financial News

May 28 Financial Quick Takes: Alphamab Oncology raises $60M; plus $180.5M for Panacea healthcare fund and more

Hudson Bay leads Alphamab Oncology's $60M series B Alphamab Oncology (Cayman) raised $60 million in a series B round led by Hudson Bay Capital, with participation from new investor and entrepreneur Adrian Cheng and existing...
BioCentury | May 24, 2018
Finance

Chasing China

While Nan Fung Life Sciences had planned to establish a longer track record in biotech investments before launching its first China-focused fund, the group accelerated its plans to capitalize on the growing Chinese biotech industry....
BioCentury | Apr 21, 2018
Finance

Qiming’s cross-border connection

Qiming Venture Partners chose to focus its first ex-China fund on healthcare because the firm sees more interest in cross-border collaborations in life sciences than some of the other industries it invests in. Qiming unveiled...
BioCentury | Apr 20, 2018
Financial News

Qiming closes three new funds

Qiming Venture Partners closed two U.S. dollar funds and one renminbi fund totaling nearly $1.4 billion on April 16. Qiming Venture USD Fund VI closed with $935 million and Qiming Venture RMB Fund V raised...
BioCentury | Apr 16, 2018
Financial News

Qiming raises $1.4B across three funds

Qiming Venture Partners closed two U.S. dollar funds and one renminbi fund totaling nearly $1.4 billion. Qiming Venture USD Fund VI closed with $935 million and Qiming Venture RMB Fund V raised RMB2.1 billion ($334.3...
BioCentury | Mar 7, 2017
Financial News

Frontline raises second RMB fund

Frontline Bioventures closed its second renminbi fund and third overall, bringing the firm's total under management to more than RMB3 billion ($435 million). Founder and Managing Partner Leon Chen declined to disclose the new fund's...
BioCentury | Feb 3, 2016
Financial News

Qiming closes Fund V at $648 million

...brings Qiming's assets under management to $2.5 billion, including five U.S. dollar funds and three RMB funds...
Items per page:
1 - 10 of 12
BioCentury | Feb 13, 2021
Finance

Qiming readies to kick off Chinese New Year with a first for Hong Kong exchange

...said Qiming typically invests 60-70% of its RMB funds...
...which manages nine U.S. dollar and six RMB funds...
BioCentury | Jan 27, 2021
Deals

Jan. 26 Quick Takes: Sanofi to manufacture more than 100M doses of Comirnaty; plus Qiming, Nirogy, Takeda-Evozyne and Vir

Under a new deal with Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), Sanofi (Euronext:SAN; NASDAQ:SNY) will produce more than 100 million doses of COVID-19 vaccine Cormirnaty in Europe in 2021. Sanofi spokesperson Nicolas Kressmann said...
BioCentury | Dec 9, 2020
Emerging Company Profile

How D3 Bio is building its biomarker-driven pipeline

George Chen’s D3 Bio is prioritizing  its internal pipeline so it can be choosy about in-licensed assets. The Shanghai company unveiled a $200 million series A round on Nov. 17 that was backed...
BioCentury | May 28, 2019
Financial News

May 28 Financial Quick Takes: Alphamab Oncology raises $60M; plus $180.5M for Panacea healthcare fund and more

Hudson Bay leads Alphamab Oncology's $60M series B Alphamab Oncology (Cayman) raised $60 million in a series B round led by Hudson Bay Capital, with participation from new investor and entrepreneur Adrian Cheng and existing...
BioCentury | May 24, 2018
Finance

Chasing China

While Nan Fung Life Sciences had planned to establish a longer track record in biotech investments before launching its first China-focused fund, the group accelerated its plans to capitalize on the growing Chinese biotech industry....
BioCentury | Apr 21, 2018
Finance

Qiming’s cross-border connection

Qiming Venture Partners chose to focus its first ex-China fund on healthcare because the firm sees more interest in cross-border collaborations in life sciences than some of the other industries it invests in. Qiming unveiled...
BioCentury | Apr 20, 2018
Financial News

Qiming closes three new funds

Qiming Venture Partners closed two U.S. dollar funds and one renminbi fund totaling nearly $1.4 billion on April 16. Qiming Venture USD Fund VI closed with $935 million and Qiming Venture RMB Fund V raised...
BioCentury | Apr 16, 2018
Financial News

Qiming raises $1.4B across three funds

Qiming Venture Partners closed two U.S. dollar funds and one renminbi fund totaling nearly $1.4 billion. Qiming Venture USD Fund VI closed with $935 million and Qiming Venture RMB Fund V raised RMB2.1 billion ($334.3...
BioCentury | Mar 7, 2017
Financial News

Frontline raises second RMB fund

Frontline Bioventures closed its second renminbi fund and third overall, bringing the firm's total under management to more than RMB3 billion ($435 million). Founder and Managing Partner Leon Chen declined to disclose the new fund's...
BioCentury | Feb 3, 2016
Financial News

Qiming closes Fund V at $648 million

...brings Qiming's assets under management to $2.5 billion, including five U.S. dollar funds and three RMB funds...
Items per page:
1 - 10 of 12